E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Respiratory Distress Syndrome |
Síndrome de Distrés Respiratorio |
|
E.1.1.1 | Medical condition in easily understood language |
Respiratory Distress Syndrome |
Síndrome de Distrés Respiratorio |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To compare the efficacy of two schemes of exogenous pulmonary surfactant administration, in RNP with RDS (One of them indicated under lung ultrasound criteria versus the other following the recommendations of the current guidelines), in terms of reducing the number of intubations in the first 72 hours of life. |
- Comparar la eficacia de dos esquemas de administración de surfactante pulmonar exógeno, en RNP con SDR (Uno de ellos indicado bajo criterios de ecografía pulmonar versus el otro siguiendo las recomendaciones de las guías actuales), en términos de disminución del número de intubaciones en las primeras 72 horas de vida. |
|
E.2.2 | Secondary objectives of the trial |
- To assess the efficacy of the early administration of exogenous surfactant compared to the usual regimen in terms of reducing the need for oxygen therapy by at least 20%. - Compare between both groups, the number of RNP that require a second dose of surfactant. - To compare the efficacy in terms of reduction in the time (days) of necessary respiratory support, in the experimental group versus the control group. - Compare the incidence of development of bronchopulmonary dysplasia (BPD) in the experimental group versus the control group. - Compare the incidence of intraventricular hemorrhage between both groups. - Compare the LUS score at 24 hours, 7 days, 14 days and 28 days of both study groups. - Compare the morbidity and mortality in the 2 groups. |
- Valorar la eficacia de la administración precoz de surfactante exógeno en comparación con el esquema habitual en términos de disminución de las necesidades de oxigenoterapia de al menos un 20%. - Comparar entre ambos grupos, el número de RNP que precisen de una segunda dosis de surfactante. - Comparar la eficacia en términos de disminución del tiempo (días) de soporte respiratorio necesario, en el grupo experimental versus el grupo control. - Comparar la incidencia del desarrollo de Displasia broncopulmonar (DBP) en el grupo experimental versus el grupo control. - Comparar la incidencia de hemorragia intraventricular entre ambos grupos. - Comparar el score LUS a las 24 horas, 7 días, 14 días y 28 días de ambos grupos en estudio. - Comparar la morbimortalidad en los 2 grupos. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The study population will be made up of premature infants under 32 weeks and/or ≤1500gr. Subjects will be assigned according to simple randomization by letter and there will be single blind masking. |
La población en estudio estará constituida por prematuros menores de 32 semanas y/o ≤1500gr. Los sujetos serán asignados de acuerdo a aleatorización simple por carta y habrá enmascaramiento simple ciego. |
|
E.4 | Principal exclusion criteria |
Non-acceptance of informed parental consent. Patients presenting any of the following conditions: - Chromosomal abnormalities or complex congenital malformations. - Congenital lung diseases. - Severe sepsis or septic shock. - Meconium aspiration syndrome. - Administration of surfactant in the delivery room. |
No aceptación del consentimiento informado de los padres. Pacientes que presenten alguna de las siguientes condiciones: - Anomalías cromosómicas o malformaciones congénitas complejas. - Enfermedades pulmonares congénitas. - Sepsis grave o shock séptico. - Síndrome de aspiración de meconio. - Administración de surfactante en la sala de partos. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Intubation rate in the next 72 hours of life. |
Tasa de intubación en las próximas 72 horas de vida. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Percentage decrease in oxygen therapy needs after surfactant administration. - Rate of administration of a second dose in both groups. - Rate of reduction in the need for respiratory support used in the experimental group versus the control group. - Percentage of development of bronchopulmonary dysplasia (DBP) in both groups. - Percentage of intraventricular hemorrhage between both groups, derived from the respiratory intervention. - LUS reduction rate at 24 hours, 7 days, 14 days and 28 days in both study groups. - Rate of morbidity and mortality in the 2 RNP groups based on the surfactant treatment criteria used. |
- Porcentaje de disminución de las necesidades de oxigenoterapia tras la administración de surfactante. - Tasa de administración de una segunda dosis en ambos grupos. - Tasa de reducción de la necesidad de soporte respiratorio utilizado en el grupo experimental versus el grupo control. - Porcentaje de desarrollo de Displasia broncopulmonar (DBP) en ambos grupos. - Porcentaje de hemorragia intraventricular entre ambos grupos, derivadas de la intervención a nivel respiratorio. - Tasa de reducción del LUS a las 24 horas, 7 días, 14 días y 28 días de ambos grupos en estudio. - Tasa de morbimortalidad en los 2 grupos de RNP en función del criterio de tratamiento con surfactante utilizado. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
24 hours, 7 days, 14 days and 28 days. |
24 horas, 7 días, 14 días y 28 días. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Ultima visita del último sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |